Login to Your Account



Fibroids Therapy in the Pipeline, Too

Repros Lifts Weighty Offering: $71M for Hypogonadism Work

By Randy Osborne
Staff Writer

Thursday, June 20, 2013
financings_resized.jpg

Plowing ahead with the second Phase III trial to evaluate Androxal (enclomiphene), the estrogen receptor antagonist for secondary hypogonadism, Repros Therapeutics Inc. priced an underwritten public offering of about 3.7 million shares at $19 each, grossing about $71.2 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription